Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

lease contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 30, 2015 Mordor Intelligence presents ... Primary Packaging Material (Plastic, Glass, Paper, Metal) - ByType of ... Pouches, Syringes, Tubes, Vials, Sachets) - By Geographical Region ( ... Asia Pacific , Latin America ... Africa ) - discussing Industry Value Chain Analysis, ...
(Date:6/29/2015)... PARK, Calif. , June 29, 2015  Nevro ... company that is providing innovative evidence-based solutions for the ... Earnhardt , President and Chief Executive Officer of Intersect ... its Board of Directors, effective June 28, 2015. ... Earnhardt has successfully led Intersect ENT, a company ...
(Date:6/29/2015)... 2015 DURECT Corporation (Nasdaq: DRRX ... , President and CEO, will be presenting at ... 8 at 11:45 a.m. Eastern Time.  The conference ... in New York City.  Investors and analysts that ... meeting through the conference organizers at http://www.cantorconferences.com/health-registration/health-investors ...
Breaking Medicine Technology:Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3Nevro Appoints Lisa Earnhardt to its Board of Directors 2DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... 14, 2011 /PRNewswire-iReach/ --   Olympus America ... collection of EZ Shot 2 single-use aspiration needles for ... puncture capability along with an adjustable sheath designed to ... in a complete selection of sizes and styles, the ...
... Specialty Pharmacy, the nation,s largest, privately owned specialty ... healthcare and specialty pharmacy executive, has joined Diplomat,s ... as an industry executive in pharma, prescription benefit ... the perfect fit to help drive Diplomat,s continued ...
Cached Medicine Technology:Olympus Broadens Portfolio With a Suite of New Single-Use Aspiration Needles 2Veteran Healthcare and Pharmacy Executive Craig Stephens Joins Diplomat Specialty Pharmacy as Group Vice President of Business Development and Trade Relations 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... scientists and analysts who are currently attending an accredited American educational institution through ... has provided new insight into healthcare, the environment, political campaigns, and a variety ...
(Date:6/30/2015)... ... ... Scott Purdy, the spokesperson for Dephinitive Systems LLC, announces today that the company will ... for eXtra Operability (XO) which was chosen to reflect the company’s commitment to health ... Provider XO, based in Cleveland OH, is part of the Cadrillion Capital family of ...
(Date:6/29/2015)... ... June 30, 2015 , ... Sublime Beauty NATURALS® introduces ... offer. The oil, ideal for natural skincare and even culinary uses, was especially ... is something most people desire, and Oil Pulling can accomplish this. Oil Pulling is ...
(Date:6/29/2015)... , ... June 30, 2015 , ... Ticket Down is ... Soldier Field over the 4th of July weekend. Concertgoers can add promo/coupon code ... only recently caught on to their innovative sound, will not want to miss what ...
(Date:6/29/2015)... ... , ... An upcoming documentary for public television by the Sports Conflict ... fresh perspective on conflict in sports with guest speakers including sports culture and marketing ... around the sports industry that will discuss challenges in competitive sports and how sports ...
Breaking Medicine News(10 mins):Health News:Izenda Offers Embedded BI and Analytics Scholarship 2Health News:Izenda Offers Embedded BI and Analytics Scholarship 3Health News:Dephinitive Systems Is Getting a New Name 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Tickets Prices in Chicago at Soldier Field 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Tickets Prices in Chicago at Soldier Field 3Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 2Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 3
... Francisco, CA May 18, 2009 Shire plc ... today announced new findings on INTUNIV (guanfacine) extended release, ... This randomized placebo controlled trial met its primary objective, ... oppositional symptoms in children aged 6 to 12 years ...
... Pa., May 18 Air Products (NYSE: ... its U.S. healthcare businesses to Landauer-Metropolitan, Inc. (LMI), the ... services in the northeast, based in Mount Vernon, N.Y. ... includes Air Products, ownership interests in certain of the ...
... breaks standing upMINNEAPOLIS, May 18 ... sight ... and you just can,t wait. It,s a common ... activities. Posing a solution to women,s restroom debacles everywhere is ... FemMed, Inc., of Minnetonka, Minn., that allows women to take ...
... -- Eularis is announcing the release of an ... Relationships & Business Through Web 2.0 and Beyond. " ... world of eMarketing and Social Media to provide Pharmaceutical ... on how to use these emerging tools. "As ...
... seek hepatitis B vaccination before going abroad , ... London, UK (PRWeb ... hepatitis B endemic areas, reveals that over 55 per cent(1) of them ... minute(2). , , , , ,More people are choosing destinations outside the ...
... Epeius Biotechnologies ( www.epeiusbiotech.com ) today ... a tumor-targeted anti-cancer agent designed to seek-out and destroy ... Rexin-G is currently approved for the treatment of all ... Biotech is conducting a series of advanced Phase I/II ...
Cached Medicine News:Health News:Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms 2Health News:Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms 3Health News:Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms 4Health News:Air Products Sells Three U.S. Healthcare Businesses to Landauer-Metropolitan 2Health News:Video: GoGirl!, Don't Take Life Sitting Down 2Health News:Eularis Releases Comprehensive Report on Effective and Measurable Pharmaceutical eMarketing Using Social Media 2Health News:GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus 2Health News:GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus 3Health News:GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus 4Health News:GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus 5Health News:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 2
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Highly concentrated daily cleaner with Microclens beads for superior cleaning action....
Medicine Products: